

研究成果の刊行に関する一覧（令和7年度）

1	Konishi K, Uehira T, Hirota K, Ueji T, Nishida Y, Shirasaka T, Watanabe D. Cancer Risk in Men with HIV in Japan: An 18-year Single-Center Cohort Study. <i>Cancers (Basel)</i> 18(2) 248, 2026.
2	Yamasaki L, Akiyama Y, Ueno K, Hoshino Y, Nagi M, Nakayama N, Abe M, Miyazaki Y, Gatanaga H, Watanabe K. Progressive Severe Hemophagocytic Syndrome due to Disseminated Histoplasmosis in a Patient with HIV-1 Infection. <i>Internal Medicine</i> 64:1113-1118, 2025.
3	Nguyen HT, Chikata T, Zhang Y, Van Tran G, Gatanaga H, Oka S, Takiguchi M. Role of HLA-B*58:01-Restricted CD8+ T Cells in HIV-1 Subtype AE Infection. <i>Journal of Infectious Diseases</i> 231:175-185, 2025.
4	Tsuchiya K, Tran HT, Kawashima A, Watanabe K, Hamada A, Oka S, Gatanaga H. High plasma concentration of tenofovir alafenamide in people living with HIV with ABCB1 genetic variants. <i>Journal of Infection and Chemotherapy</i> 31:102541, 2025.
5	Ando N, Mizushima D, Takano M, Mitobe M, Kobayashi K, Kubota H, Miyake H, Suzuki J, Sadamasu K, Aoki T, Watanabe K, Oka S, Gatanaga H. Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant <i>Mycoplasma genitalium</i> . <i>Journal of Antimicrobial Chemotherapy</i> 80:247-253, 2025.
6	Kitamura H, Ando N, Mizushima D, Shiojiri D, Nakamoto T, Takano M, Gatanaga H. Electrocautery ablation therapy for anal intraepithelial carcinoma with high-resolution anoscopy. <i>Journal of Infection and Chemotherapy</i> 31:102608, 2025.
7	Rockstroh JK, Paredes R, Cahn P, Molina JM, Sokhela SM, Hineiro F, Kassim S, Cunningham D, Ghosn J, Bogner JR, Gatanaga H, Asante-Appiah E, Zhang Y, Nwoke U, Klopfer SO, Eves K, Squires K, Correll T, Fox MC, Pisculli ML. Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial. <i>Clinical Infectious Diseases</i> 81:322-332, 2025.
8	Nakano K, Kawashima A, Nakamoto T, Nakamichi K, Kuwata R, Abe S, Inoue E, Ando N, Uemura H, Mizushima D, Aoki T, Teruya K, Gatanaga H. Early diagnosis of progressive multifocal leukoencephalopathy in untreated HIV infection via ultrasensitive PCR testing for JC virus: A case report. <i>IDCases</i> 40: e02229, 2025.
9	Adachi E, Yokomaku Y, Watanabe D, Gatanaga H, Oka S, Shirasaka T, Wakatabe R, Chamay N, Sutton K, Sutherland-Phillips D, Urbaitye R, D'Amico R, van Wyk J. Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial. <i>Journal of Infection and Chemotherapy</i> 31:102734, 2025.
10	Abe S, Mizushima D, Ando N, Kawashima A, Uemura H, Shibata S, Moro H, Kikuchi T, Gatanaga H, Oka S, Shiojiri D. Doxycycline pre-exposure prophylaxis prevents sexually transmitted infections without affecting vaginal bacterial flora in female sex workers. <i>JAC Antimicrobial Resistance</i> 7, dlaf054, 2025.
11	Kawashima A, Yanagawa Y, Chikata T, Shimogawara R, Mizushima D, Tsuchiya K, Yagita K, Gatanaga H, Watanabe K. Optimization of TaqMan-based quantitative PCR diagnosis for <i>Entamoeba histolytica</i> using droplet digital PCR. <i>PLoS Neglected Tropical Diseases</i> 19: e0012935, 2025.
12	Abe S, Nakamoto T, Aoki T, Teruya K, Gatanaga H. HIV-associated multicentric Castleman disease with Kaposi sarcoma: A case report with 120-week follow-up of HHV-8 after remission. <i>Journal of Infection and Chemotherapy</i> 31:10286, 2025.
13	Hasegawa K, Kawashima A, Kuwata R, Shimogawara R, Sasaki M, Yanagawa Y, Nakamoto T, Aoki T, Yagita K, Watanabe K, Teruya K, Gatanaga H. Intrathoracic rupture of amebic liver abscess: a case report and literature review. <i>Tropical Medicine and Health</i> 53:136, 2025.
14	Adachi E, Yokomaku Y, Watanabe D, Gatanaga H, Oka S, Shirasaka T, D'Amico R, Sutton K, Sutherland-Phillips D, Roberts J, Thornhill J, Murungi A, Brown K. Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study. <i>Journal of Infection and Chemotherapy</i> 31:102834, 2025.
15	Nagai R, Gatanaga H, Uemura H, Ogata M, Kubota S, Yamamoto M, Hara H, Oka S, Hiroi Y. Coronary artery stenosis in Japanese hemophiliacs living with HIV-1 progressed dramatically over two years. <i>Global Health and Medicine</i> 7:384-390, 2025.
16	Chikata T, Kuroki K, Kuse N, Kliszczak AE, Paes W, Tomioka N, Parker R, Aflalo A, Akahoshi T, Zhang Y, Yamashita R, Sakata R, Kusaka H, Watanabe Y, Nicastri A, Matsubara H, Ose T, Kita S, Oka S, Gatanaga H, Lin Z, Ternette N, Borrow P, Maenaka K, Takiguchi M. Molecular basis for selection and inhibition of HIV-1 escape virus by T cells and KIR2DL2+NK cells. <i>Nature Communications</i> 16:9796, 2025.

17	Nguyen HT, Chikata T, Kuse N, Zhang Y, Pham DTN, Do NT, Nguyen TC, Lung NB, Bui HTM, Gatanaga H, Van Tran G, Nguyen BT, Van Nguyen D, Giang LM, Oka S, Takiguchi M. HIV-1-specific CD8+ T cells with different abilities to recognize HIV-1-infected cells in HIV-1-exposed seronegative individuals. PNAS Nexus 4, pgaf336, 2025.
18	Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, Goto H, Endo T, Teshima T, Yang Y, Nakagawa M. Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma. Leukemia.39: 243-247, 2025.
19	Shiratori S, Suto K, Hasegawa Y, Ara T, Matsukawa T, Goto H, Onozawa M, Nakagawa M, Kahata K, Hidaka D, Ogasawara R, Okada K, Sugita J, Kakinoki Y, Ota S, Hashimoto D, Teshima T. Safety and efficacy of GVHD prophylaxis with mini-dose methotrexate in umbilical cord blood transplantation - NJHSG-CBT18 observational study. Transplant Cell Ther. S2666-6367, 2025.
20	Hiroshi Moro, The Iron-infection Axis Revisited: From Mechanistic Insights to Therapeutic Frontiers 2025 Nov;31(11): doi: 10.1016/j.jiac.2025.102818. Epub Sep 25 2025.
21	Yokomaku Y, Noda T, Imahashi M, Nishioka Y, Myojin T, et al. Antiretroviral therapies and status of people living with HIV in Japan: An update from hospital survey and national database. PLoS One 20 e0317655, 2025.
22	Iwatani Y, Matsuoka K, Ode H, Kubota M, Nakata Y, et al. The unique structure of the highly conserved PPLP region in HIV-1 Vif is critical for the formation of APOBEC3 recognition interfaces. mBio 16 e0333224, 2025.
23	Hill AO, Kaneko N, Amos N, Bourne A, Imahashi M, et al. High suicidality rates among LGB+ youth in Japan: Demographic and psychosocial correlates. J Affect Disord 119468, 2025.
24	Makiko Kamijo, Tohru Taniuchi, Kaori Kubo, Tamayo Watanabe, People Living with HIV in Japan Exhibit Situation-Specific Optimism Regarding the Progression to Acquired Immunodeficiency Syndrome (AIDS), AIDS Behav, 29, 3245-3252, 2025.
25	Teruhisa Fujii, Keiji Nogami, Akihiro Sawada, Azusa Nagao, Chiai Nagae, Masanori Nojima, Nobuaki Suzuki, Mika Kawano, Tomomi Shimura, Yoshimasa Sugao, Kagehiro Amano. TSUBASA study: evaluation of the quality and content of daily life of people with hemophilia A without factor VIII inhibitors on prophylactic treatment with emicizumab. Res Pract Thromb Haemost, 9. e-102971, 2025.
26	Amano K, Fujii T, Sawada A, Nagao A, Nagae C, Nojima M, Suzuki N, Kawano M, Shimura T, Sugao Y, Hattori N, Nogami K. TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab. Haemophilia, 31, 14-23, 2025.
27	Goto Y, Ahn YM, Toyoda M, Hamana H, Jin Y, Aritsu Y, Nakama T, Tajima Y, Maddumage JC, Li H, Kitamatsu M, Kishi H, Yonekawa A, Jayasinghe D, Shimono N, Nagasaki Y, Minami R, Toya T, Sekiya N, Tomita Y, Chatzileontiadou DSM, Nakata H, Nakagawa S, Sakagami T, Ueno T, Gras S, Motozono C. Molecular basis of potent antiviral HLA-C-restricted CD8+ T cell response to an immunodominant SARS-CoV-2 nucleocapsid epitope. Nat Commun. 16 8062, 2025.
28	Adachi E, Minami R, Shirano M, Nakamura H, Fukushima K, Imahashi M, Sekiya R, Yoshino Y, Taniguchi T Evaluation of cabotegravir plus rilpivirine in routine clinical settings in Japan: A multicentre study of efficacy, safety and biomarker dynamics J - HIV RWD Collaborative Database Team. HIV Med. 26 1673-1683, 2025.
29	Ndubi M, Toyoda M, Ngare I, Motozono C, Minami R, Ueno T SARS-CoV-2 Spike-specific T cell responses following COVID-19 vaccination in Japanese people living with HIV. Jpn J Infect Dis. doi: 10.7883/yoken. JJID. 086. 2025.
30	Yokomaku Y, Teruya K, Watanabe D, Endo T, Minami R, Taguchi N, Cassidy T, Marongiu A, Thorpe D, Shirasaka T, Oka S. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort. PLoS One 20 e0313338, 2025.
31	Konishi K, Uehira T, Hirota K, Ueki T, Nishida Y, Shirasaka T, Watanabe D. The shifting burden of mortality among men with HIV in Japan between 2007 and 2024: a single-center retrospective cohort study. BMC Infect Dis 25(1) 1694, 2025.
32	遠藤知之、後藤秀樹、松川敏大、荒隆英、長谷川祐太、須藤啓斗、宮島徹、永井惇、豊嶋崇徳 2剤療法施行中のHIV陽性者におけるBlipおよびTarget Not Detected (TND) 維持率の検討 日本エイズ学会誌 27 56-63 2025.

33	吉田繁、佐藤かおり、藤澤真一、岩崎澄央、遠藤知之、豊嶋崇徳、松田昌和、今橋真弓、蜂谷敦子、岡田清美、齊藤浩一、奥田美那子、加藤真吾、林田庸総、椎野禎一郎、西澤雅子、杉浦互、吉村和久、菊地正 プロテアーゼ、逆転写酵素、インテグラーゼを対象としたHIV薬剤耐性検査試薬キット、HIV-1 Genotyping Kit with Integraseの性能評価 日本エイズ学会誌 27 69-78 2025.
34	松川敏大、遠藤知之、森木朝子、永井惇、宮島徹、長谷川祐太、荒隆英、後藤秀樹、豊嶋崇徳 AIDS患者の髄液病原体網羅の解析を目的としたマルチプレックスPCRの有用性についての検討 日本エイズ学会誌 27 147-153 2025.
35	安達大紀 HIVスティグマの低減に向けた一考案 ―HIV診療科所属心理士の視点から― 仙台医療センター医学雑誌 Vol. 15, 2025.
36	上條慎子, 谷内通, 久保かおり, 渡邊珠代. 北陸地方 HIV 陽性者における 抗 HIV 薬の服薬アドヒアランスおよび性格特性の関連. 日本エイズ学会誌. 27:12-21, 2025.
37	渡邊 大 あなたに知ってほしいこと 渡邊 大 あなたに知ってほしいこと 大阪P1-14 2025.
38	長尾梓、近澤悠志、兼松毅、山崎尚也、野島正寛、寛井透雄、天野景裕、澤田暁宏、鈴木伸明、竹谷英之、日笠聡、藤井輝久、松下正. 成人血友病患者における心血管疾患コホート研究ADVANCE Japanー合併症及び治療薬に関する中間サブ解析. 臨床血液, 66, 1438-1448 2025.
39	藤井 健司, 大東 敏和, 板村 まりの, 石井 聡一郎, 山崎 尚也, 藤井 輝久, 松尾 裕彰. ドルテグラビルとカルバマゼピンの薬物相互作用に対して抗てんかん発作薬を変更したHIV感染症の1例. 日病薬誌, 61, 511-515 2025.
40	矢倉裕輝 非がん患者の症状緩和と薬剤の使い方HIV 内田まやこ 緩和ケア薬ケースファイル じほう社 東京 191-196 2025.